将转移淋巴结数目纳入甲状腺髓样癌分期系统:验证改良版美国癌症联合委员会肿瘤-淋巴结-转移分期系统
本研究基于监测、流行病学和最终结果(SEER)数据库1175例甲状腺髓样癌(MTC)患者,并用上海第十人民医院、同济大学医学院、徐州市中心医院和苏州市第九人民医院的多中心312例数据验证,按转移淋巴结数目重新定义N分类并提出改良AJCC(mAJCC)分期。mAJCC分期的C指数为0.78(CI,0.73-0.84),高于现行AJCC分期的0.72(CI,0.67-0.78),多中心数据生存分析结果相似。
要点
- 按转移淋巴结数目将N分类定义为N'0(0枚)、N'1(1-9枚)、N'2(≥10枚)。
- mAJCC分期C指数0.78(CI,0.73-0.84),现行AJCC分期为0.72(CI,0.67-0.78)。
- 作者认为以转移淋巴结数目替代淋巴结位置改良AJCC分期是可行且合适的。
核心结论
- mAJCC分期比现行AJCC分期更有效地判别MTC患者的预后,作者认为通过引入转移淋巴结数目替代淋巴结位置来改良现行AJCC分期是可行且合适的。
- 这些发现可能被下一版AJCC分期系统采纳,并用于指导临床实践。
研究设计与样本
- 本研究基于SEER数据库数据,并由上海第十人民医院、同济大学医学院、徐州市中心医院和苏州市第九人民医院的多中心数据验证。
- SEER数据库共纳入1175例MTC患者,中国三家医院共纳入312例。
- 采用Cox比例风险回归分析估计风险比及其95%置信区间(CI),用一致性指数(C-index)评价现行AJCC肿瘤-淋巴结-转移(TNM)分期系统与改良AJCC(mAJCC)TNM分期系统的判别准确性。
主要发现
- 按转移淋巴结数目重新定义N分类:N'0类(0枚转移淋巴结)、N'1类(1-9枚转移淋巴结)、N'2类(≥10枚转移淋巴结)。
- mAJCC分期将肿瘤重新分为四期:I期(T1-4N'0M0、T1N'1M0)、II期(T2-3N'1M0、T1N'2M0)、III期(T4N'1M0、T2-4N'2M0)、IV期(TanyN'anyM1)。
- 现行AJCC分期的C指数为0.72(CI,0.67-0.78),mAJCC分期的C指数为0.78(CI,0.73-0.84)。
- 多中心数据集的生存分析观察到相似结果。
关键数值与推荐
- N'0类为0枚转移淋巴结,N'1类为1-9枚转移淋巴结,N'2类为≥10枚转移淋巴结。
- mAJCC分期I期为T1-4N'0M0、T1N'1M0;II期为T2-3N'1M0、T1N'2M0;III期为T4N'1M0、T2-4N'2M0;IV期为TanyN'anyM1。
- 现行AJCC分期C指数0.72(CI,0.67-0.78) vs mAJCC分期C指数0.78(CI,0.73-0.84)。
临床怎么用
- 作者认为mAJCC分期较现行AJCC分期能更有效判别MTC患者预后,并认为引入转移淋巴结数目替代淋巴结位置改良现行AJCC分期是可行且合适的。
- 作者提出这些发现可能被下一版AJCC分期系统采纳,并用于指导临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The current American Joint Committee on Cancer (AJCC) staging system (8th edition) for medullary thyroid cancer (MTC) was originally extrapolated from the staging system for differentiated thyroid cancer. However, the current staging system does not accurately predict the prognosis of patients with MTC. Patients and Methods: The present study was based on data from the Surveillance, Epidemiology, and End Results (SEER) database and validated by multicenter data from the Shanghai Tenth People's Hospital, Tongji University School of Medicine, Xuzhou City Central Hospital, and Suzhou Ninth People's Hospital. Hazard ratio with its 95% confidence interval [CI] was estimated by Cox proportional hazards regression analysis. The concordance index (C-index) was used to evaluate the discrimination accuracy of the current AJCC tumor-node-metastasis (TNM) staging system and the modified AJCC (mAJCC) TNM staging system. Results: A total of 1175 MTC patients were selected from the SEER database and 312 from the three hospitals in China. We redefined the N category according to the number of metastatic lymph nodes (LNs) as follows: N'0 category (0 metastatic LNs), N'1 category (1-9 metastatic LNs), and N'2 category (≥10 metastatic LNs). The four distinct tumor stages were reclassified in the mAJCC staging system as follows: stage I (T1-4N'0M0, T1N'1M0), stage II (T2-3N'1M0, T1N'2M0), stage III (T4N'1M0, T2-4N'2M0), and stage IV (TanyN'anyM1). The C-index of the current AJCC staging system and the mAJCC staging system was 0.72 [CI, 0.67-0.78] and 0.78 [CI, 0.73-0.84], respectively. Similar results were observed in the survival analysis of the multicenter data set. Conclusions: The mAJCC staging system could discriminate the prognosis of MTC patients more effectively than the current AJCC staging system, indicating that it is feasible and appropriate to modify the current AJCC staging system by introducing the number of metastatic LNs instead of the location of LNs. These findings might be adopted in the next edition of the AJCC staging system and be used to guide clinical practice.
引用
- Wang Z, Tang C, Wang Y, et al. Inclusion of the Number of Metastatic Lymph Nodes in the Staging System for Medullary Thyroid Cancer: Validating a Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System. Thyroid. 2022. PMID: 35350868. doi:10.1089/thy.2021.0571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。